Understanding how tumors and immune cells interact in kidney cancer treatment
Official title: Tumor and immune determinants of effective anti-tumor immunity in renal cell carcinoma
Funded at Yale University · NIH-10888152 · Data updated 2026-11-12
This study is looking at how the immune system responds to kidney cancer and aims to find out why some people do better with certain treatments called immune checkpoint inhibitors, so we can create more tailored treatment plans for patients with kidney cancer.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | July 14, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $628,445 |
| NIH project number | 5R37CA279822-02 |
| Project ID | NIH-10888152 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with advanced renal cell carcinoma who are considering or currently receiving immune checkpoint inhibitor therapy.
✕Less likely to help
Patients with early-stage kidney cancer or those not receiving immunotherapy may not benefit from this research.
What this research studies
This research investigates the immune response to kidney cancer, specifically focusing on how immune checkpoint inhibitors (ICIs) can be more effective. It aims to identify the specific tumor and immune characteristics that influence the success of these treatments. By analyzing the tumor microenvironment and the behavior of CD8+ T cells, the study seeks to uncover why some patients benefit from ICIs while others do not. This could lead to more personalized treatment strategies for patients with renal cell carcinoma.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for kidney cancer patients, enhancing the effectiveness of immunotherapy.
How similar studies have gone: Previous research has shown promise in understanding immune responses in other cancers, but this approach is particularly novel for renal cell carcinoma.
Where this research is happening
-
Yale University
New Haven, United States Active
Researchers
- Principal investigator: Braun, David — Yale University
- Study coordinator: Braun, David
Related research
Other NIH-funded projects on the same topics.
-
Understanding how kidney cancer spreads to bone and how to fight it
A patient-focused look at how clear cell renal cell carcinoma spreads to bone and how new treatments might help people with advanced disease.
-
Improve precision medicine for kidney cancer in people of African descent
A research project will explore why kidney cancer affects people of African ancestry differently and how to use genomics to guide better treatments.
-
Engineering immunogenic cell death to boost melanoma and kidney cancer therapy
This grant supports research aimed at making melanoma and kidney cancer cells die in a way that triggers a stronger immune response in patients.
-
Prognostic test to predict metastasis in clear cell kidney cancer
A new 12-marker biomarker test for people with clear cell renal cell carcinoma may help doctors predict which patients are at higher risk of metastasis.
-
Defining metabolic targets in kidney cancer for new treatments
A cancer-focused project is exploring how kidney cancer uses metabolism so doctors can find new, targeted ways to treat it.
-
Targeting HIF2 in kidney cancer: a new approach for clear cell RCC
A kidney cancer research program tests whether blocking HIF2 can slow or stop tumors in people with clear cell renal cell carcinoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.